Description
LuciAmb 5 MG (Ambrisentan) is a selective endothelin type-A receptor antagonist (ETA receptor antagonist) an orally bioavailable, small-molecule targeted agent that blocks endothelin-1 (ET-1)-mediated vasoconstriction and pulmonary vascular remodeling in pulmonary arterial hypertension (PAH) supplied as tablets in 5 mg strength in a 30-tablet pack and manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos. Its active ingredient, ambrisentan INN, selectively antagonises the endothelin type-A (ETA) receptor, blocking ET-1-driven pulmonary vasoconstriction, smooth muscle cell proliferation, and vascular remodelling that progressively elevates pulmonary arterial pressure and right ventricular afterload across WHO Group 1 pulmonary arterial hypertension.
In the pivotal Phase 3 ARIES-1 trial, ambrisentan 5 mg once daily achieved a placebo-corrected improvement in 6-minute walk distance (6MWD) of +31 metres at week 12 (p=0.008) in PAH patients, with significant reductions in time to clinical worsening versus placebo. In the landmark Phase 3 AMBITION trial combining ambrisentan with tadalafil as initial combination therapy, the regimen reduced the risk of clinical failure events by 50% compared with monotherapy (hazard ratio 0.50; 95% CI 0.35–0.72; p<0.001), establishing initial combination ERA plus PDE5 inhibitor therapy as a guideline-recommended first-line standard of care for newly diagnosed PAH. Searching for LuciAmb 5 MG Ambrisentan? Mediaid Pharmacy lists this product across its cardiovascular medicines, pulmonary arterial hypertension medicines, and Lucius Pharmaceuticals portfolios and ships it worldwide.
Basic Product Information of LuciAmb 5 MG (Ambrisentan)
| Brand Name | LuciAmb 5 MG (Ambrisentan) |
| Product Name | LuciAmb |
| Generic Name | Ambrisentan INN |
| Drug Class | Selective Endothelin Type-A Receptor Antagonist (ETA Receptor Antagonist); Endothelin Receptor Antagonist (ERA); Pulmonary Arterial Hypertension (PAH) Agent; Cardiovascular Agent; Targeted Pulmonary Vasodilator; Antiproliferative Vascular Agent |
| Formulation | Tablet (Oral) |
| Available Strengths | 5 mg per tablet |
| Available Pack Size | 30 Tablets per Pack |
| Dosing & Dose Modification | Starting dose: 5 mg once daily, orally, with or without food. Dose escalation: May be increased to 10 mg once daily if the 5 mg dose is tolerated and additional efficacy is desired; this requires availability of the 10 mg tablet strength. Cyclosporine interaction: Limit ambrisentan dose to 5 mg once daily in patients receiving concomitant cyclosporine cyclosporine approximately doubles ambrisentan exposure and the dose must not exceed 5 mg once daily in this combination. Swallow tablets whole do not crush, split, or chew LuciAmb tablets. Do not exceed 5 mg once daily with cyclosporine co-administration. |
| Primary Indications | Pulmonary arterial hypertension (PAH, WHO Group 1) in adult patients to improve exercise capacity and delay clinical worsening. LuciAmb (Ambrisentan) is used as monotherapy or as part of combination PAH therapy, including combination with a phosphodiesterase type-5 (PDE5) inhibitor such as tadalafil, as supported by the AMBITION Phase 3 trial. Each treatment decision must account for WHO functional class, haemodynamic profile, and concomitant medications always consult the full prescribing information and the treating pulmonologist or cardiologist. |
| Manufacturer | Lucius Pharmaceuticals (Lao) Co., Ltd., Laos |
| Country of Origin | Laos |
| Originator Reference Brands | Letairis® (ambrisentan tablets, by Gilead Sciences approved in the United States); Volibris® (ambrisentan tablets, by GlaxoSmithKline approved in the European Union and other territories). Both originator brands contain ambrisentan INN as the active pharmaceutical ingredient in the same selective ETA receptor antagonist drug class. LuciAmb is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is supplied through Mediaid Pharmacy for international procurement. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at room temperature (15°C to 30°C). Keep in the original packaging and protect from moisture. Keep out of the reach of children. |
How LuciAmb (Ambrisentan) Works: Selective Endothelin Type-A Receptor Antagonism in Pulmonary Arterial Hypertension
Ambrisentan INN is an orally bioavailable, propanoic acid-class, small-molecule antagonist that selectively blocks the endothelin type-A (ETA) receptor one of two G-protein-coupled receptor subtypes (ETA and ETB) through which endothelin-1 (ET-1) exerts its vascular effects. ET-1 is a 21-amino acid peptide produced by vascular endothelial cells and is among the most potent endogenous vasoconstrictors identified in human physiology. ET-1 acts via both ETA receptors located predominantly on vascular smooth muscle cells and mediating sustained vasoconstriction, smooth muscle proliferation, and fibrosis and ETB receptors, located on endothelial cells and involved in ET-1 clearance and nitric oxide-mediated vasodilation. In pulmonary arterial hypertension (PAH, WHO Group 1), circulating and locally expressed ET-1 concentrations are markedly elevated; elevated ET-1 drives progressive pulmonary vasoconstriction, intimal and medial vascular wall remodelling, and in situ thrombosis that together increase pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP), ultimately imposing rising right ventricular afterload and leading to right heart failure. By selectively antagonising ETA receptors, ambrisentan competitively prevents ET-1 from binding to and activating ETA on pulmonary arterial smooth muscle cells, blocking ET-1-driven vasoconstriction, vascular smooth muscle cell proliferation, and collagen deposition without fully suppressing ETB-mediated ET-1 clearance and endothelial nitric oxide production. Pre-clinical binding studies characterised ambrisentan’s ETA selectivity at greater than 4,000-fold versus ETB, confirming highly selective ETA antagonism that distinguishes it from non-selective dual ETA/ETB antagonists such as bosentan.
The clinical consequence of selective ETA blockade in PAH is a measurable reduction in pulmonary vascular resistance, improvement in exercise capacity (measured by 6-minute walk distance), and delay in clinical worsening events including disease progression, hospitalisation for PAH, and death. ETA selectivity preserves ETB-mediated functions including clearance of circulating ET-1 and local vasodilatory nitric oxide release from pulmonary endothelial cells which may contribute to ambrisentan’s clinical tolerability profile, including a lower incidence of hepatotoxicity compared with earlier non-selective ERA agents.
Pharmacokinetically, ambrisentan exhibits dose-proportional pharmacokinetics with a mean terminal half-life (t½) of approximately 9 hours in healthy subjects, supporting reliable once-daily oral dosing. Ambrisentan is predominantly metabolised via glucuronidation (UGT1A9S, UGT2B7S) and oxidation (CYP3A4, CYP2C19, CYP3A5); co-administration with cyclosporine, a potent organic anion transport inhibitor, approximately doubles ambrisentan exposure and limits the permitted dose to 5 mg once daily. Ambrisentan is not a clinically significant inhibitor or inducer of major CYP enzymes at therapeutic doses, reducing the risk of pharmacokinetic drug–drug interactions compared with bosentan, which induces CYP3A4 and CYP2C9. Ambrisentan does not produce significant liver enzyme elevations at approved doses, differentiating its hepatic safety profile from bosentan-class non-selective ERAs. For the complete range of cardiovascular and pulmonary hypertension medicines available at Mediaid Pharmacy, visit the cardiovascular medicines collection.
LuciAmb 5 MG (Ambrisentan): Indications, Dosing, and Key Safety Information
| Approved Indications | Pulmonary Arterial Hypertension (PAH, WHO Group 1): Treatment of adult patients with PAH to improve exercise capacity and delay clinical worsening. LuciAmb is indicated for use as monotherapy and as part of combination therapy, including combination with a PDE5 inhibitor such as tadalafil, as supported by the AMBITION Phase 3 trial. |
| Recommended Starting Dose | PAH (standard initiation): 5 mg once daily orally, with or without food (1× LuciAmb 5 MG tablet once daily). Dose escalation: May be increased to 10 mg once daily if the 5 mg dose is well tolerated, subject to availability of the 10 mg tablet strength. With cyclosporine: Do not exceed 5 mg once daily; cyclosporine co-administration approximately doubles ambrisentan plasma exposure. Swallow LuciAmb tablets whole do not crush, split, or chew. |
| Dose Titration & Modification | Ambrisentan does not require routine dose titration in the way that platelet-count-based agents do; the 5 mg once-daily dose is the established starting and, for many patients, maintenance dose. Dose escalation to 10 mg once daily may be considered based on individual tolerability and clinical response. Dose reduction or discontinuation may be required for hepatic enzyme elevations (>3× upper limit of normal [ULN]), symptomatic fluid retention or peripheral oedema requiring intervention, or confirmed pregnancy. In cyclosporine co-administration, cap the dose at 5 mg once daily throughout the course of combined therapy. |
| Missed Dose | If a dose of LuciAmb (Ambrisentan) is missed, take it as soon as remembered on the same day. If it is not remembered until the next day, skip the missed dose and resume with the next scheduled once-daily dose. Do not take two doses in one day to compensate for a missed dose. Take LuciAmb at the same time each day to maintain consistent plasma levels. |
| Key Warnings & Precautions | Embryo-Fetal Toxicity: Ambrisentan is teratogenic and causes major birth defects. LuciAmb (Ambrisentan) is contraindicated in pregnancy. Females of reproductive potential must use two reliable methods of contraception during LuciAmb treatment and for at least one month after the final dose. Conduct a pregnancy test before initiating therapy and monthly thereafter. Breastfeeding is not recommended during LuciAmb treatment.
Fluid Retention and Peripheral Oedema: Peripheral oedema and fluid retention including cases severe enough to require intervention with diuretics or hospitalisation have been reported with ambrisentan. Monitor patients for signs of fluid retention. If clinically significant fluid retention develops, evaluate to determine the cause and initiate appropriate treatment or dose modification. Pulmonary Oedema with Pulmonary Veno-Occlusive Disease (PVOD): Should signs of pulmonary oedema develop, consider the possibility of associated PVOD. Ambrisentan is not recommended for patients with PVOD; discontinue immediately if PVOD is confirmed. Decreased Haemoglobin / Anaemia: Decreases in haemoglobin and haematocrit have been observed with ambrisentan use. Measure haemoglobin at baseline and periodically during treatment. Clinically significant decreases in haemoglobin may require dose modification or transfusion support. Hepatotoxicity: Elevations in liver aminotransferases (ALT, AST) have been reported. Monitor liver function tests (LFTs) before initiating LuciAmb and periodically thereafter, particularly if symptoms of liver injury (jaundice, fatigue, nausea, right upper quadrant pain) develop. Discontinue LuciAmb if aminotransferases exceed 5× ULN or if liver injury is clinically confirmed. Interaction with Cyclosporine: Co-administration with cyclosporine approximately doubles ambrisentan exposure. Limit LuciAmb to 5 mg once daily in patients receiving concomitant cyclosporine throughout the duration of combined therapy. |
| Common Adverse Reactions (≥10%) | Peripheral oedema, nasal congestion, sinusitis, flushing, palpitations, nasopharyngitis, abdominal pain, constipation, and dyspnoea. Anaemia (decrease in haemoglobin) is reported in approximately 7–15% of patients. Fluid retention requiring diuretic intervention has been reported. These reactions are generally manageable with dose monitoring and supportive care under the treating specialist’s guidance. |
| Drug Interactions | Ambrisentan is a substrate of UGT1A9, UGT2B7, CYP3A4, and CYP2C19 enzymes and of P-glycoprotein (P-gp) and organic anion transporting polypeptides (OATP1B1, OATP1B3). Cyclosporine: Cyclosporine, a potent OATP inhibitor, approximately doubles ambrisentan area under the curve (AUC) limit LuciAmb dose to 5 mg once daily with concomitant cyclosporine. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir): may moderately increase ambrisentan exposure; monitor for adverse reactions and consider dose adjustment. Rifampin (CYP3A4 inducer): Rifampin markedly reduces ambrisentan exposure in the first few days of co-administration followed by partial recovery; monitor clinical response. PDE5 inhibitors (sildenafil, tadalafil): No clinically significant pharmacokinetic interaction; ambrisentan combined with tadalafil is supported by the AMBITION trial. Disclose all concomitant medications, supplements, and immunosuppressants to the treating pulmonologist or cardiologist before initiating LuciAmb. |
| Hepatic Impairment | Ambrisentan has not been studied in patients with clinically significant hepatic impairment (Child-Pugh Class B or C). The use of LuciAmb in patients with pre-existing moderate to severe hepatic impairment is not recommended. Monitor liver function tests (LFTs) at baseline and periodically throughout treatment. Discontinue if serum aminotransferases exceed 5× ULN or if signs of clinical liver injury appear. Consult the treating hepatologist and pulmonologist for individualised guidance in patients with hepatic comorbidities. |
| Pregnancy & Lactation | Ambrisentan is contraindicated in pregnancy it is teratogenic and may cause major birth defects and foetal death based on animal data and its mechanism of action as an endothelin receptor antagonist, given the established role of the ET-1/endothelin receptor axis in normal cardiovascular and craniofacial foetal development. Females of reproductive potential must use two reliable and complementary forms of contraception during LuciAmb treatment and for at least one month after the final dose. A pregnancy test must be performed before initiating LuciAmb and monthly throughout treatment. Breastfeeding is not recommended during LuciAmb treatment and for a clinically appropriate washout period thereafter. Notify the treating pulmonologist or cardiologist immediately if pregnancy occurs during ambrisentan treatment. |
Who Should Use LuciAmb 5 MG (Ambrisentan)?
LuciAmb 5 MG (Ambrisentan) is indicated for adult patients with pulmonary arterial hypertension (PAH, WHO Group 1) a progressive, life-limiting disease characterised by elevated pulmonary vascular resistance, right ventricular pressure overload, and, if untreated, progressive right heart failure and death. PAH encompasses idiopathic PAH (iPAH), heritable PAH (hPAH), PAH associated with connective tissue disease (CTD-PAH, including systemic sclerosis and systemic lupus erythematosus), PAH associated with congenital heart disease (CHD-PAH), PAH associated with human immunodeficiency virus (HIV-PAH), and portopulmonary hypertension all of which may be treated with ambrisentan within the WHO Group 1 classification.
First, newly diagnosed PAH patients in WHO Functional Class II or III constitute the primary indication population for LuciAmb (Ambrisentan). In newly diagnosed PAH, current international guidelines (ESC/ERS 2022, AHA/ACC) recommend initial combination therapy with an ERA plus a PDE5 inhibitor in eligible patients the AMBITION Phase 3 trial (500 patients, ambrisentan 10 mg plus tadalafil 40 mg versus monotherapy) demonstrated that initial combination therapy reduced the risk of clinical failure events by 50% versus monotherapy (HR 0.50; 95% CI 0.35–0.72; p<0.001), establishing this regimen as a guideline-endorsed first-line standard of care in treatment-naive PAH.
Second, patients with established PAH who remain symptomatic or experience disease progression on PDE5 inhibitor monotherapy may add ambrisentan as sequential combination therapy to achieve sequential dual-pathway inhibition of the nitric oxide pathway and the ET-1 pathway.
Third, PAH patients who are intolerant of or have contraindications to PDE5 inhibitors, soluble guanylate cyclase (sGC) stimulators, or prostacyclin-class agents may use LuciAmb as ERA monotherapy when the selective ETA mechanism is the appropriate first-line approach based on the patient’s haemodynamic profile, comorbidities, and WHO functional class. LuciAmb is contraindicated in pregnancy, in patients with clinically significant pre-existing hepatic impairment, and in patients with known hypersensitivity to ambrisentan or any excipient. Pulmonary veno-occlusive disease (PVOD) is not an appropriate indication for ambrisentan; vasodilator therapy may precipitate acute pulmonary oedema in PVOD, requiring immediate discontinuation.
The treating cardiologist or pulmonologist must conduct a full right heart catheterisation (RHC)-confirmed haemodynamic evaluation, echocardiographic assessment, six-minute walk test (6MWT), and WHO functional class stratification before initiating LuciAmb, and must review all concomitant medications particularly cyclosporine, immunosuppressants, and any other PAH therapies before prescribing. Specialist centres co-sourcing LuciAmb alongside complementary PAH agents or cardiovascular medicines can browse the Mediaid Pharmacy pulmonary arterial hypertension medicines and cardiovascular medicines portfolios for the full selection available for international delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for LuciAmb 5 MG (Ambrisentan)
Mediaid Pharmacy is a Dhaka-based supplier of specialty cardiovascular and pulmonary hypertension medicines with worldwide shipping to patients, pulmonology clinics, cardiology centres, transplant programmes, and international distributors across all regions. LuciAmb 5 MG (Ambrisentan), manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is supplied as 30 tablets per pack in 5 mg strength with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order. The 5 mg strength covers the established starting and principal maintenance dose of ambrisentan across its approved PAH indication, enabling PAH clinics and pulmonology programmes to implement WHO functional class–guided initial combination therapy (ambrisentan 5 mg plus a PDE5 inhibitor) and ERA monotherapy regimens from a single supplier relationship.
Pulmonary hypertension centres, cardiology programmes managing PAH-CTD, transplant programmes with cyclosporine-managed patients, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding LuciAmb Ambrisentan stock availability, current pricing, and international delivery timelines to their country. Procurement teams co-sourcing LuciAmb with other cardiovascular or targeted pulmonary vascular medicines can browse the complete Mediaid Pharmacy cardiovascular medicines collection and the Lucius Pharmaceuticals medicines portfolio before requesting a consolidated quotation.
Why Choose LuciAmb 5 MG (Ambrisentan) from Mediaid Pharmacy?
LuciAmb 5 MG (Ambrisentan) provides pulmonologists, cardiologists, and specialist PAH clinics with a mechanistically targeted, guideline-recommended selective ETA receptor antagonist backed by three landmark Phase 3 clinical trials ARIES-1, ARIES-2, and AMBITION that collectively establish ambrisentan as a foundational pillar of modern PAH pharmacotherapy. In the ARIES-1 Phase 3 trial (202 patients), ambrisentan 5 mg once daily delivered a placebo-corrected improvement in 6-minute walk distance (6MWD) of +31 metres at week 12 (p=0.008), with significant time to clinical worsening benefit. ARIES-2 (192 patients) demonstrated that ambrisentan 5 mg once daily produced a placebo-corrected 6MWD improvement of +59 metres at week 12, confirming consistent exercise capacity benefit across two independent Phase 3 trials.
The transformative AMBITION trial (500 treatment-naive patients) established that initial combination therapy with ambrisentan plus tadalafil reduced the risk of clinical failure events by 50% versus either monotherapy (HR 0.50; 95% CI 0.35–0.72; p<0.001), with a 46% reduction in first hospitalisation for PAH and a 63% reduction in disease progression events placing ambrisentan-based combination therapy at the centre of ESC/ERS 2022 and AHA/ACC PAH guideline recommendations for newly diagnosed intermediate-to-high-risk patients. Ambrisentan’s selective ETA mechanism differentiates it from non-selective dual ETA/ETB endothelin receptor antagonists such as bosentan ETA selectivity preserves ETB-mediated ET-1 clearance and endothelial nitric oxide production, contributing to ambrisentan’s improved hepatic tolerability profile (no mandatory monthly LFT monitoring under current Letairis labelling following hepatotoxicity signal update) and lower discontinuation rate due to aminotransferase elevations compared with bosentan.
LuciAmb is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is available through Mediaid Pharmacy with full product documentation, specialist supply coordination, and worldwide shipping from Dhaka. To source additional Lucius Pharmaceuticals cardiovascular and pulmonary hypertension medicines, visit the Mediaid Pharmacy Lucius Pharmaceuticals medicines section and the pulmonary arterial hypertension medicines portfolio, and contact the team for a personalised quotation.
Frequently Asked Questions About LuciAmb 5 MG (Ambrisentan)
What is LuciAmb 5 MG (Ambrisentan) used for?
LuciAmb 5 MG (Ambrisentan) is a selective endothelin type-A (ETA) receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH, WHO Group 1) in adult patients to improve exercise capacity and delay clinical worsening. LuciAmb is used as monotherapy or in combination with a PDE5 inhibitor such as tadalafil, as supported by the AMBITION Phase 3 trial, which showed a 50% reduction in clinical failure risk with ambrisentan plus tadalafil versus monotherapy. The originator brands for ambrisentan are Letairis® (Gilead Sciences, United States) and Volibris® (GlaxoSmithKline, European Union and other territories). LuciAmb, manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is available through Mediaid Pharmacy with worldwide shipping to patients, PAH clinics, and specialist centres.
What is the generic name of LuciAmb?
The generic name of LuciAmb is ambrisentan INN. LuciAmb is the brand name registered by Lucius Pharmaceuticals (Lao) Co., Ltd. for ambrisentan manufactured in Laos. LuciAmb is formulated as oral tablets in 5 mg strength, supplied in a 30-tablet pack. The 5 mg strength covers the approved starting and principal maintenance dose for pulmonary arterial hypertension across both monotherapy and initial combination therapy regimens with a PDE5 inhibitor. The originator reference brands are Letairis® (Gilead Sciences) and Volibris® (GlaxoSmithKline). Mediaid Pharmacy distributes LuciAmb globally with worldwide shipping to patients, pulmonology centres, cardiology hospitals, and specialist PAH clinics.
What is the difference between LuciAmb (Ambrisentan) and Letairis / Volibris (Ambrisentan)?
LuciAmb, Letairis®, and Volibris® all contain ambrisentan INN as the active pharmaceutical ingredient and share the same selective ETA receptor antagonist mechanism of action in pulmonary arterial hypertension. Letairis® is the originator brand by Gilead Sciences marketed in the United States in 5 mg and 10 mg tablet strengths; Volibris® is the same molecule marketed by GlaxoSmithKline in the European Union and other territories, also in 5 mg and 10 mg strengths. LuciAmb is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is supplied in the 5 mg strength covering the established starting and maintenance dose for PAH available through Mediaid Pharmacy for international procurement by specialist centres and patients in regions where Letairis® or Volibris® may be unavailable or cost-prohibitive. For the full range of pulmonary arterial hypertension medicines at Mediaid Pharmacy, visit the pulmonary arterial hypertension medicines collection.
How is LuciAmb 5 MG (Ambrisentan) administered?
LuciAmb (Ambrisentan) is administered orally once daily (at the same time each day), with or without food. The standard starting dose is 5 mg once daily; the dose may be increased to 10 mg once daily if the 5 mg dose is well tolerated and additional clinical benefit is sought. Swallow LuciAmb tablets whole with water do not crush, split, or chew the tablets. If a dose is missed, take it as soon as remembered on the same day; if not remembered until the next day, skip the missed dose and continue with the next regularly scheduled dose. Do not take two doses in one day. If co-administering with cyclosporine, the LuciAmb dose must not exceed 5 mg once daily throughout the period of combined therapy. Do not abruptly discontinue LuciAmb without consulting the treating pulmonologist or cardiologist, as disease progression may occur with discontinuation of PAH therapy.
What are the side effects of LuciAmb 5 MG (Ambrisentan)?
The most common adverse reactions of ambrisentan occurring in 10% or more of patients in clinical trials include peripheral oedema, nasal congestion, sinusitis, flushing, palpitations, nasopharyngitis, abdominal pain, and constipation. Fluid retention and peripheral oedema are among the most frequently reported adverse reactions; in some patients fluid retention is severe enough to require diuretic therapy or hospitalisation, and dose modification may be needed. Decreases in haemoglobin (anaemia) have been reported in approximately 7–15% of patients and should be monitored at baseline and periodically during treatment. Hepatic aminotransferase elevations (ALT, AST) have been reported less frequently than with non-selective ERA agents; nonetheless, liver function tests should be monitored at baseline and if symptoms of liver injury develop. Embryo-fetal toxicity is the most serious risk ambrisentan is teratogenic and contraindicated in pregnancy, requiring reliable contraception throughout treatment. Always discuss the complete safety profile, individual risk factors, and monitoring requirements with the treating pulmonologist or cardiologist before and throughout LuciAmb treatment.
How effective is Ambrisentan (LuciAmb) for pulmonary arterial hypertension?
Ambrisentan has demonstrated statistically significant and clinically meaningful efficacy in PAH across three major Phase 3 trials. In ARIES-1 (202 patients), ambrisentan 5 mg once daily produced a placebo-corrected improvement in 6-minute walk distance (6MWD) of +31 metres at week 12 (p=0.008), with significant delay in time to clinical worsening. In ARIES-2 (192 patients), ambrisentan 5 mg once daily achieved a placebo-corrected 6MWD improvement of +59 metres at week 12, with consistent exercise capacity benefit and significant time to clinical worsening reduction. In the landmark AMBITION trial (500 treatment-naive patients), initial combination therapy with ambrisentan plus tadalafil reduced the risk of clinical failure events by 50% versus either monotherapy (HR 0.50; 95% CI 0.35–0.72; p<0.001), reduced first hospitalisation for PAH by 46%, and reduced disease progression events by 63% establishing this dual-pathway combination as the guideline-preferred first-line strategy in newly diagnosed intermediate-to-high-risk PAH. LuciAmb delivers the same active ingredient ambrisentan INN at the approved 5 mg tablet dose, sourced through Mediaid Pharmacy with worldwide shipping. For the complete cardiovascular medicines range at Mediaid Pharmacy, visit the cardiovascular medicines collection.
Is LuciAmb 5 MG (Ambrisentan) safe during pregnancy or while breastfeeding?
No. Ambrisentan is contraindicated in pregnancy it is teratogenic and may cause major birth defects and foetal death. The endothelin receptor axis plays a critical role in normal cardiovascular and craniofacial foetal development; blockade of ETA receptors during foetal organogenesis poses a serious developmental risk based on animal reproductive studies. LuciAmb must not be used during pregnancy. Females of reproductive potential must use two reliable and complementary methods of contraception during LuciAmb treatment and for at least one month after the final dose. A pregnancy test must be performed before initiating treatment and monthly during treatment. Breastfeeding is not recommended during LuciAmb treatment and for an appropriate washout period after the final dose. If pregnancy occurs during ambrisentan treatment, the treating pulmonologist or cardiologist must be notified immediately and LuciAmb discontinued. Consult the treating specialist before starting LuciAmb in patients of reproductive potential.
Can I order LuciAmb 5 MG (Ambrisentan) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies LuciAmb 5 MG (Ambrisentan) to patients, pulmonology centres, cardiology hospitals, specialist PAH clinics, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order LuciAmb 5 MG (Ambrisentan) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.